RNA interference

This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

The EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the

Latest news

ICER says Alnylam’s Onpattro should cost 90%-95% less

In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’antisense candidate Tegsedi (inotersen) which is due for an FDA
Alnylam claims first RNAi approval from FDA for patisiran

Alnylam’s faith in the gene-silencing potential of RNA interference (RNAi) drugs has finally paid off, with the US approval of its patisiran candidate for rare disease hereditary ATTR amyloidosis. ... RNAi drugs are used to block gene expression,
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The green light sets up the first product approval for Alnylam, an RNA interference specialist which has been working on gene-silencing drugs for around 15 years and is also due ... RNA process that results in TTR protein expression.
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The green light sets up the first product approval for Alnylam, an RNA interference specialist which has been working on gene-silencing drugs for around 15 years and is also due ... RNA process that results in TTR protein expression.
FDA lifts clinical hold on Sanofi’s haemophilia drug

The RNA interference drug, which targets antithrombin (AT), can now resume phase II and III trials in patients with haemophilia A and B without inhibitors, which were suspended after one patient

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest appointments

Silence appoints chief medical officer

These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Medical Director: Highly Competitive

Experienced Editor, London, Medical Communications: Competitive package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Director: Highly Competitive Salary &Benefits

Account Director - Digital: Great salary and benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Director – Head of Public Affairs: Neg

Account Director: Negotiable

Director Healthcare PR Communications: Salary TBC

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Editorial Director – Medical Education: Neg

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Associate Medical Director: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Executive – Medical Communications: Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Scientific Team Lead: Competitive Salary

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...